

# Rosaria Talarico

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9225341/rosaria-talarico-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81  
papers

1,383  
citations

20  
h-index

34  
g-index

91  
ext. papers

1,695  
ext. citations

3.9  
avg, IF

4.37  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 81 | Classification criteria for Sjogren's syndrome: a critical review. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 9-14  | 15.5 | 95        |
| 80 | Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 1281-6   | 3.9  | 72        |
| 79 | The diagnosis and classification of mixed connective tissue disease. <i>Journal of Autoimmunity</i> , <b>2014</b> , 48-49, 46-9   | 15.5 | 72        |
| 78 | Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 369   | 5.6  | 68        |
| 77 | Behçet's syndrome: a critical digest of the 2014-2015 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S3-14   | 2.2  | 62        |
| 76 | A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 380 | 5.6  | 57        |
| 75 | Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000782  | 5.9  | 53        |
| 74 | Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2233-2240                                  | 3.9  | 52        |
| 73 | Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 277  | 5.7  | 46        |
| 72 | Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000783  | 5.9  | 42        |
| 71 | A clinical prediction rule for lymphoma development in primary Sjögren's syndrome. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 804-8   | 4.1  | 41        |
| 70 | Behçet's syndrome: a critical digest of the 2013-2014 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S112-22   | 2.2  | 39        |
| 69 | Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. <i>Muscle and Nerve</i> , <b>2016</b> , 54, 666-72   | 3.4  | 30        |
| 68 | Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behçet's Disease. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1858  | 1.8  | 28        |
| 67 | Relapsing polychondritis: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000788  | 5.9  | 24        |
| 66 | One year in review 2016: spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 3-17  | 2.2  | 24        |
| 65 | Vitamin D in "early" primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?. <i>Rheumatology International</i> , <b>2014</b> , 34, 1159-64  | 3.6  | 23        |

|    |  |      |    |
|----|--|------|----|
| 64 | Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000785  | 5.9  | 21 |
| 63 | One year in review 2017: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 721-734   | 2.2  | 21 |
| 62 | Successful treatment of refractory adult-onset still disease with canakinumab: a case report. <i>Journal of Clinical Rheumatology</i> , <b>2014</b> , 20, 121  | 1.1  | 20 |
| 61 | Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e518-e519   | 14.2 | 20 |
| 60 | Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 103-108   | 2.3  | 19 |
| 59 | Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 296  | 5.6  | 17 |
| 58 | Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 451675                                     | 4.3  | 17 |
| 57 | Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin?. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S55-8  | 2.2  | 17 |
| 56 | One year in review 2016: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 357-72  | 2.2  | 17 |
| 55 | Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1098-1104               | 2.4  | 16 |
| 54 | Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000789   | 5.9  | 16 |
| 53 | The interaction between autoimmune diseases and fibromyalgia: risk, disease course and management. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 1069-76  | 5.1  | 15 |
| 52 | Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. <i>Journal of Leukocyte Biology</i> , <b>2016</b> , 99, 761-9 | 6.5  | 14 |
| 51 | Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000786   | 5.9  | 14 |
| 50 | Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000783  | 5.9  | 14 |
| 49 | Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 918                      | 5.6  | 13 |
| 48 | The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 177-184  | 8.1  | 12 |
| 47 | Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000790  | 5.9  | 12 |

|    |  |     |    |
|----|--|-----|----|
| 46 | One year in review 2016: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 10-22  | 2.2 | 12 |
| 45 | IgG4-related diseases: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000787  | 5.9 | 11 |
| 44 | Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]. <i>RMD Open</i> , <b>2018</b> , 4, e000784   | 5.9 | 11 |
| 43 | One year in review: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 102-8  | 2.2 | 11 |
| 42 | Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, S130-8  | 2.2 | 10 |
| 41 | One year in review 2017: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 108, 3-15   | 2.2 | 9  |
| 40 | One year in review 2019: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 3-17   | 2.2 | 9  |
| 39 | Development of de novo major involvement during follow-up in Behçet's syndrome. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 247-50  | 3.9 | 8  |
| 38 | Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1170 | 1.8 | 8  |
| 37 | Epidemiology and management of neuropsychiatric disorders in Behçet's syndrome. <i>CNS Drugs</i> , <b>2015</b> , 29, 189-96  | 6.7 | 8  |
| 36 | One year in review 2018: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 13-27  | 2.2 | 8  |
| 35 | Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study. <i>Clinical Rheumatology</i> , <b>2013</b> , 32, 1547-8   | 3.9 | 7  |
| 34 | One year in review 2018: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 111, 12-32  | 2.2 | 7  |
| 33 | Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 42                         | 4.9 | 6  |
| 32 | One year in review 2020: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 127, 3-10   | 2.2 | 6  |
| 31 | Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , <b>2014</b> , 5, 95-100   | 3.7 | 5  |
| 30 | Sexual dysfunction in Behçet's syndrome. <i>Rheumatology International</i> , <b>2020</b> , 40, 9-15  | 3.6 | 5  |
| 29 | Behçet's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease?. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 125-128   | 2.2 | 5  |

|    |  |     |   |
|----|--|-----|---|
| 28 | Systemic vasculitis and the lung. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 45-50   | 5.3 | 4 |
| 27 | A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease. <i>BioMed Research International</i> , <b>2015</b> , 2015, 120519   | 3   | 4 |
| 26 | Shaping the Future of Rare Diseases after a Global Health Emergency: Organisational Points to Consider. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,                           | 4.6 | 4 |
| 25 | RarERN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 347 | 4.2 | 3 |
| 24 | One year in review 2017: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 103, 5-26   | 2.2 | 3 |
| 23 | One year in review 2019: vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 117, 3-19  | 2.2 | 3 |
| 22 | Being a caregiver of a Behçet's syndrome patient: challenges and perspectives during a complex journey. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 436   | 4.2 | 2 |
| 21 | Behçet's syndrome and ocular involvement: changes over time. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 127, 86-93   | 2.2 | 2 |
| 20 | Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies. <i>RMD Open</i> , <b>2021</b> , 7,  | 5.9 | 2 |
| 19 | COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 203-213   | 2.2 | 2 |
| 18 | Skin Manifestations and Sjögren's Syndrome <b>2014</b> , 207-215   |     | 1 |
| 17 | One year in review 2020: vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 124, 3-14  | 2.2 | 1 |
| 16 | COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 203-213   | 2.2 | 1 |
| 15 | One year in review 2021: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 129, 3-12   | 2.2 | 1 |
| 14 | One year in review 2021: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 3-12   | 2.2 | 1 |
| 13 | Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: a prospective observational study. <i>Joint Bone Spine</i> , <b>2014</b> , 81, 378-9                  | 2.9 | 0 |
| 12 | Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , <b>2020</b> , 6, 0                 | 5.9 | 0 |
| 11 | Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 769870   | 4.9 | 0 |

|    |  |     |
|----|--|-----|
| 10 | Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 2917-2923  | 3.9 |
| 9  | Taux d'infections sŕies chez les patients atteints de polyarthrite rhumatoŕide recevant une biothŕapie anti-TNF alpha : Œtude observationnelle prospective. Commentaire de l'article de Che et al.. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2015</b> , 82, 66-67 | 0.1 |
| 8  | Morphologic ultrasonography of the temporal artery for diagnosis of giant cell arteritis: Brief report. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 717-719   | 3.3 |
| 7  | Behŕt Disease <b>2016</b> , 225-232  |     |
| 6  | Skin Manifestations and Cryoglobulinemia <b>2014</b> , 329-335   |     |
| 5  | Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1036-1043  | 2.2 |
| 4  | One year in review 2021: Behŕt's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 3-13  | 2.2 |
| 3  | Adherence to treatment in Behŕt's syndrome: a multi-faceted issue. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 88-93   | 2.2 |
| 2  | Empowering rare disease patients through patient education: the new BehŕTalk programme.. <i>BMC Rheumatology</i> , <b>2022</b> , 6, 17   | 2.9 |
| 1  | Systemic vasculitis: one year in review 2022.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 673-687   | 2.2 |